Stuart Kushner

1.8k total citations
19 papers, 1.2k citations indexed

About

Stuart Kushner is a scholar working on Psychiatry and Mental health, Pharmacology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Stuart Kushner has authored 19 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 6 papers in Pharmacology and 5 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Stuart Kushner's work include Schizophrenia research and treatment (16 papers), Bipolar Disorder and Treatment (7 papers) and Treatment of Major Depression (5 papers). Stuart Kushner is often cited by papers focused on Schizophrenia research and treatment (16 papers), Bipolar Disorder and Treatment (7 papers) and Treatment of Major Depression (5 papers). Stuart Kushner collaborates with scholars based in United States, Belgium and Canada. Stuart Kushner's co-authors include Jorge A. Quiroz, Magali Haas, Mariëlle Eerdekens, William H. Olson, Vivek Kusumakar, Akbar Ali Khan, Keith Karcher, Rosanne Lane, Ilse Van Hove and Gahan Pandina and has published in prestigious journals such as Biological Psychiatry, The British Journal of Psychiatry and Journal of the American Academy of Child & Adolescent Psychiatry.

In The Last Decade

Stuart Kushner

19 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stuart Kushner United States 14 1.0k 250 208 119 117 19 1.2k
Taro Iwamoto United States 10 1.2k 1.1× 265 1.1× 209 1.0× 162 1.4× 61 0.5× 14 1.4k
Ludmila Kryzhanovskaya United States 17 830 0.8× 255 1.0× 149 0.7× 87 0.7× 77 0.7× 29 1.1k
Michelle Kramer United States 15 1.6k 1.6× 254 1.0× 172 0.8× 283 2.4× 80 0.7× 27 1.9k
Judith C. Kando United States 15 741 0.7× 135 0.5× 199 1.0× 264 2.2× 71 0.6× 40 1.2k
Ilse Augustyns United States 7 665 0.6× 192 0.8× 164 0.8× 54 0.5× 59 0.5× 7 738
Bruno Pfuhlmann Germany 21 501 0.5× 216 0.9× 133 0.6× 229 1.9× 80 0.7× 76 1.1k
Maju Mathews United States 18 702 0.7× 204 0.8× 104 0.5× 300 2.5× 40 0.3× 73 1.0k
Thomas J. Arndt United States 8 760 0.7× 147 0.6× 57 0.3× 171 1.4× 57 0.5× 8 1.1k
Nigel Bark United States 13 666 0.6× 275 1.1× 66 0.3× 79 0.7× 153 1.3× 30 1.2k
WFSBP Task Force on Treatment Guide United States 8 1.1k 1.0× 274 1.1× 110 0.5× 408 3.4× 63 0.5× 8 1.4k

Countries citing papers authored by Stuart Kushner

Since Specialization
Citations

This map shows the geographic impact of Stuart Kushner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stuart Kushner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stuart Kushner more than expected).

Fields of papers citing papers by Stuart Kushner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stuart Kushner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stuart Kushner. The network helps show where Stuart Kushner may publish in the future.

Co-authorship network of co-authors of Stuart Kushner

This figure shows the co-authorship network connecting the top 25 collaborators of Stuart Kushner. A scholar is included among the top collaborators of Stuart Kushner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stuart Kushner. Stuart Kushner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Kent, Justine, Stuart Kushner, Xiaoping Ning, et al.. (2012). Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study. Journal of Autism and Developmental Disorders. 43(8). 1773–1783. 87 indexed citations
2.
Pandina, Gahan, Stuart Kushner, Keith Karcher, & Magali Haas. (2012). An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. Child and Adolescent Psychiatry and Mental Health. 6(1). 23–23. 17 indexed citations
3.
4.
Quiroz, Jorge A., et al.. (2011). Deltoid injections of risperidone long-acting injectable in patients with schizophrenia.. PubMed. 8(6). 20–8. 12 indexed citations
5.
Quiroz, Jorge A., Lakshmi N. Yatham, Joseph Palumbo, et al.. (2010). Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder. Biological Psychiatry. 68(2). 156–162. 104 indexed citations
6.
Kramer, Michelle, George M. Simpson, Valentinas Mačiulis, et al.. (2010). One-Year Open-Label Safety and Efficacy Study of Paliperidone Extended-Release Tablets in Patients With Schizophrenia. CNS Spectrums. 15(8). 506–514. 11 indexed citations
7.
Haas, Magali, Alan S. Unis, Jorge L. Armenteros, et al.. (2009). A 6-Week, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Risperidone in Adolescents with Schizophrenia. Journal of Child and Adolescent Psychopharmacology. 19(6). 611–621. 100 indexed citations
8.
Haas, Magali, Melissa P. DelBello, Gahan Pandina, et al.. (2009). Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double‐blind, placebo‐controlled study. Bipolar Disorders. 11(7). 687–700. 120 indexed citations
9.
Haas, Magali, Mariëlle Eerdekens, Stuart Kushner, et al.. (2009). Efficacy, safety and tolerability of two risperidone dosing regimens in adolescent schizophrenia: double-blind study. The British Journal of Psychiatry. 194(2). 158–164. 78 indexed citations
10.
Kramer, Michelle, George M. Simpson, Valentinas Mačiulis, et al.. (2007). Paliperidone Extended-Release Tablets for Prevention of Symptom Recurrence in Patients With Schizophrenia. Journal of Clinical Psychopharmacology. 27(1). 6–14. 169 indexed citations
11.
12.
13.
Mintzer, Jacobo, Andrew Greenspan, Ivo Caers, et al.. (2006). Risperidone in the Treatment of Psychosis of Alzheimer Disease: Results From a Prospective Clinical Trial. American Journal of Geriatric Psychiatry. 14(3). 280–291. 69 indexed citations
14.
Lindenmayer, Jean‐Pierre, Akbar Ali Khan, Mariëlle Eerdekens, Ilse Van Hove, & Stuart Kushner. (2006). Long-term safety and tolerability of long-acting injectable risperidone in patients with schizophrenia or schizoaffective disorder. European Neuropsychopharmacology. 17(2). 138–144. 38 indexed citations
15.
Kushner, Stuart, Akbar Ali Khan, Rosanne Lane, & William H. Olson. (2006). Topiramate monotherapy in the management of acute mania: results of four double‐blind placebo‐controlled trials. Bipolar Disorders. 8(1). 15–27. 123 indexed citations
16.
Kramer, Michelle, Stuart Kushner, Ujjwala Vijapurkar, Pilar Lim, & Mariëlle Eerdekens. (2006). P.3.a.041 Delaying symptom recurrence in patients with schizophrenia treated with paliperidone extended-release tablets. European Neuropsychopharmacology. 16. S387–S387. 1 indexed citations
17.
DelBello, Melissa P., Robert L. Findling, Stuart Kushner, et al.. (2005). A Pilot Controlled Trial of Topiramate for Mania in Children and Adolescents With Bipolar Disorder. Journal of the American Academy of Child & Adolescent Psychiatry. 44(6). 539–547. 99 indexed citations
18.
Apter, Jeffrey, Stuart Kushner, & Robert L. Woolfolk. (1994). Bupropion/Nortriptyline Combination for Refractory Depression. Annals of Clinical Psychiatry. 6(4). 255–258. 5 indexed citations
19.
Merriam, Arnold E., Stanley R. Kay, Lewis A. Opler, Stuart Kushner, & H. M. van Praag. (1990). Neurological signs and the positive-negative dimension in schizophrenia. Biological Psychiatry. 28(3). 181–192. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Taro Iwamoto Breakdown of academic impact, for papers by Ludmila Kryzhanovskaya Breakdown of academic impact, for papers by Michelle Kramer Breakdown of academic impact, for papers by Judith C. Kando Breakdown of academic impact, for papers by Ilse Augustyns Breakdown of academic impact, for papers by Bruno Pfuhlmann Breakdown of academic impact, for papers by Maju Mathews Breakdown of academic impact, for papers by Thomas J. Arndt Breakdown of academic impact, for papers by Nigel Bark Breakdown of academic impact, for papers by WFSBP Task Force on Treatment Guide
Rankless by CCL
2026